Sort
17,054 grants matching “genome editing”
Enhancing Genome Editing Technology with Natural Cas9 Inhibitors
$351,255Erik J Sontheimer · Univ Of Massachusetts Med Sch Worcester · R01 · FY2019 · GM
Apollo - Universal Infrastructure for Genome Curation
$351,173Ian H Holmes · University Of California Berkeley · R01 · FY2021 · GM
Ethical Issues Surrounding Human Germline Genome Editing
$351,158Kathleen M Vogel · Arizona State University · · FY2021 · SBE
Defining the function and mechanism of regulatory ribosomal ubiquitylation
$351,146Eric J Bennett · University Of California, San Diego · R01 · FY2021 · GM
Defining DNA resection and protein localization changes that occur during DSB repair
$351,066Chris Richardson · University Of California Santa Barbara · R35 · FY2025 · GM
Development of protein-based nanostructures activated by ultrasound
$351,002Sangpil Yoon · University Of Oklahoma · R01 · FY2025 · GM
Regulation of Lipid Storage by mTORC1
$351,000Dave Bridges · University Of Michigan At Ann Arbor · R01 · FY2020 · DK
Regulation of Lipid Storage by mTORC1
$351,000Dave Bridges · University Of Michigan At Ann Arbor · R01 · FY2019 · DK
Computational modeling of DNA methylation-mediated gene regulation
$350,896John R. Edwards · Washington University · R01 · FY2020 · LM
ALS/FTD mutant C9orf72-induced genetic and nuclear pathology in iPS cell models
$350,830Jeffrey D Rothstein · Johns Hopkins University · R01 · FY2014 · NS
Regulation of TAL1/SCL in T-Cell Leukemia
$350,674Suming Huang · University Of Florida · R01 · FY2017 · CA
Enhancing Genome Editing Technology with Natural Cas9 Inhibitors
$350,593Erik J Sontheimer · Univ Of Massachusetts Med Sch Worcester · R01 · FY2021 · GM
Enhancing Genome Editing Technology with Natural Cas9 Inhibitors
$350,593Erik J Sontheimer · Univ Of Massachusetts Med Sch Worcester · R01 · FY2020 · GM
A stalled chromatin regulatory network that mediates the oncogenic activity of Meningioma-1
$350,480Kathrin M Bernt · Children'S Hosp Of Philadelphia · R01 · FY2022 · CA
A comprehensive quality control testing strategy for engineered cells
$350,457Christopher John Tompkins · Kromatid, Inc. · R44 · FY2022 · TR
THIS RESEARCH ALIGNS WITH AREA 5E OF THE BRAG RFA, MODELING APPROACHES TO UNDERSTAND THE IMPACT OF GENETIC ENGINEERING FOR POPULATION SUPPRESSION OR ALTERATION (GENE DRIVE, RELEASE OF INSECT CARRY DOMINANT LETHAL, ETC.) ON TARGET POPULATIONS OR NON-TARGET SPECIES THAT INTERACT WITH THE TARGETED SPECIES, ESPECIALLY WHEN INCORPORATING BIOLOGICALLY REALISTIC PARAMETERS (E.G. OF RESISTANCE EVOLUTION, NUMBERS OF INDIVIDUALS RELEASED, ETC.)OUR GOALS ARE (1) TO ASSESS THE RISKS OF GENOME EDITING TECHNOLOGIES, SUCH AS CRISPR-CAS9, WHEN USED TO MAKE GENE DRIVES TO SUPPRESS POPULATIONS OF CROP PESTS; (2) TO ASSESS THE EFFECT OF GENETIC BACKGROUND ON THE SPREAD OF GENE DRIVES; AND, TO IDENTIFY AND CHARACTERIZE DRIVE RESISTANT MUTATIONS PRE-EXISTING IN WILD POPULATIONS OR CREATED BY FEATURES OF CRISPR/CAS 9 ITSELF ; AND, (3) TO INCORPORATE OUR EXPERIMENTAL FINDINGS INTO MODELS OF GENE DRIVE.WE PROPOSE TO CONSTRUCT GENE DRIVES AND INTRODUCE THEM INTO POPULATIONS OF THE FLOUR BEETLE TRIBOLIUM CASTANEUM, A STORAGE GRAIN PEST. WE WILL IDENTIFY KEY FACTORS GOVERNING THE SPREAD OF GENE DRIVES IN WILD POPULATIONS AND IN GENETICALLY SUBDIVIDED POPULATIONS COMPARABLE TO REGIONAL AGRICULTURAL FIELDS. WE WILL DEVELOP GENE DRIVES ON GENETIC BACKGROUNDS SIMILAR TO AND DIVERGENT FROM THE LABORATORY STRAINS AND CHARACTERIZE THE GENETIC FEATURES OF POPULATIONS THAT REDUCE DRIVE EFFICIENCY. OUR RESULTS AND METHODS WILL INFORM THE DEVELOPMENT OF GUIDELINES FOR REGULATORY AGENCIES CHARGED WITH EVALUATING THE LIKELIHOOD OF SUCCESS OF PROPOSED DRIVE RELEASES.WE PROPOSE TO ASSESS THE BIOLOGICAL RISKS ASSOCIATED WITH THE PROPOSED USE OF GENE DRIVES BASED ON CRISPR-CAS9 GENOME EDITING TECHNOLOGY TO CONTROL CROP PESTS. MOREOVER, WE PROPOSE TO CONSTRUCT AND EVALUATE THE EFFICACY OF DRIVE REVERSAL SAFEGUARDS FOR CONTROLLING OR STOPPING THE SPREAD OF ARTIFICIAL GENE DRIVES AND PREVENTING FUTURE SPREAD OF A DRIVE TARGETING THE SAME REGION WITHIN A GENE OF INTEREST.
$350,270Trustees Of Indiana University · · FY2019 · National Institute of Food and Agriculture
A Resource Center for Tetrahymena Thermophila
$350,240Theodore G Clark · Cornell University · P40 · FY2020 · OD
Establishing a Novel Instrumental Model for Elucidating Mitochondrial DNA-Associated Dysfunction and Pathogenicity
$350,210Zengyi Shao · Iowa State University · R35 · FY2021 · GM
Studies of Allostery between Multi-domain Proteins and Nucleic Acid Complexes
$350,050Victor S Batista · Yale University · R01 · FY2024 · GM
Vitamin D and Progestins for the Chemoprevention of Fallopian Tube/Ovarian Cancer
$350,005Gustavo Rodriguez · Endeavor Health Clinical Operations · R01 · FY2022 · CA
Genotypic Interactions in Brain Cancer Heterogeneity
$350,000Frank Furnari · Ludwig Institute For Cancer Res Ltd · R01 · FY2019 · NS
Collaborative Research: Data-driven engineering of the yeast Kluyveromyces marxianus for enhanced protein secretion
$350,000Ian Wheeldon · University Of California-Riverside · · FY2024 · ENG
Integrated biochemical and bioinformatic technologies for accurate transcriptome-wide full-length RNA assembly.
$350,000Michael Joseph Lodes · Lucigen Corporation · R41 · FY2015 · HG
An early-intervention gene-editing therapeutic for Pulmonary Arterial Hypertension
$350,000Vinod Jaskula-Ranga · Hunterian Medicine Llc · R43 · FY2023 · HL
Genotypic Interactions in Brain Cancer Heterogeneity
$350,000Frank Furnari · Ludwig Institute For Cancer Res Ltd · R01 · FY2018 · NS